S. 1967 118th Congress
PBM Act
Latest action, Jun 14, 2023: Read twice and referred to the Committee on Finance.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
7 cosponsors
Sponsored by Robert Menendez (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
3 D · 4 R
- Democrat
- Republican
- Independent
Referred to: Senate: Finance Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
AMERICAN MEDICAL ASSOCIATION
LOPER CONSULTING LLC
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)
RED+BLUE STRATEGIES
7 reports
AMGEN
THE MCMANUS GROUP
6 reports
6 reports
6 reports
EMD SERONO, INC.
THE MCMANUS GROUP
6 reports
GENENTECH
THE MCMANUS GROUP
6 reports
All 25 of 35 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERICAN MEDICAL ASSOCIATION | LOPER CONSULTING LLC | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| AMGEN INC | 7 | $20.1M | Q4 2023 | Q3 2024 | yes | |
| CVS HEALTH (AND SUBSIDIARIES) | 7 | $14.0M | Q4 2023 | Q3 2024 | yes | |
| EMD SERONO INC | 7 | $4.7M | Q4 2023 | Q3 2024 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.2M | Q4 2023 | Q3 2024 | yes | |
| KAISER FOUNDATION HEALTH PLAN INC | 7 | $4.4M | Q4 2023 | Q3 2024 | yes | |
| NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 7 | $2.5M | Q4 2023 | Q3 2024 | yes | |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 7 | $469K | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | RED+BLUE STRATEGIES | 7 | $490K | Q4 2023 | Q3 2024 | yes |
| THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) | 7 | $13.5M | Q4 2023 | Q3 2024 | yes | |
| AMGEN | THE MCMANUS GROUP | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| BIOGEN | 6 | $6.2M | Q4 2023 | Q3 2024 | yes | |
| ELEVANCE HEALTH, INC. | 6 | $8.8M | Q4 2023 | Q3 2024 | yes | |
| EMD SERONO, INC. | THE MCMANUS GROUP | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| GENENTECH | THE MCMANUS GROUP | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| NOVARTIS | 6 | $8.3M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 6 | $43.8M | Q4 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | THE MCMANUS GROUP | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| GILEAD SCIENCES, INC. | THE MCMANUS GROUP | 5 | $0 | Q2 2023 | Q3 2024 | yes |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | BLUESTONE STRATEGIES, LLC | 5 | $280K | Q4 2023 | Q2 2024 | yes |
| BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) | 4 | $1.0M | Q1 2024 | Q3 2024 | yes | |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 4 | $17.5M | Q4 2023 | Q1 2024 | yes | |
| ALNYLAM PHARMACEUTICALS | THE MCMANUS GROUP | 3 | $50K | Q4 2023 | Q3 2023 | yes |
| CIGNA CORPORATION | INVARIANT LLC | 3 | $270K | Q4 2023 | Q1 2024 | yes |
| DIGESTIVE HEALTH PHYSICIANS ASSOCIATION, INC. | THE MCMANUS GROUP | 3 | $210K | Q4 2023 | Q3 2023 | yes |